CM Rekha Gupta inaugurates SSB Multispeciality Hospital in Kailash Colony

New Delhi: Delhi Chief Minister Rekha Gupta on Sunday inaugurated the SSB Multispeciality Hospital in Kailash Colony, which aims to provide round-the-clock medical services at reasonable rates, officials said.

The hospital features advanced services such as a robotic knee replacement facility and has dedicated departments for gastroenterology, respiratory care, nephrology, and neuro and spine surgery, they said.

Hospital chairperson Shyam Sundar Bansal said it will soon apply for empanelment under the Ayushman Bharat health insurance scheme of the Centre, news agency PTI reported.  

Also Read:CM Rekha Gupta Rolls Out NextGen HIMS for Easy Online OPD Appointments

Speaking at the event, Gupta said, according to a World Health Organization (WHO) report, India has less than one hospital bed available per 1,000 people, stressing that such challenges can be addressed if the government and the private sector work in tandem in a focused manner.

Delhi government aims to develop the national capital into a global medical hub, drawing patients from across the country and abroad, she said.

The chief minister mentioned the recent installation of an advanced machine at the GB Pant Hospital that can generate a complete DNA profile from just a single drop of blood as a step in this direction.

She also claimed that many hospitals constructed during the tenure of the previous (AAP) government were left incomplete or lacked sufficient resources.

“We are now bringing all such hospitals under the public-private partnership (PPP) model to ensure their full-scale functioning,” Gupta said, reports PTI.   

BJP MP Bansuri Swaraj and local MLA Shikha Rai were present at the inauguration ceremony.  

Also Read:CM Rekha Gupta announces plan for 7 Super-Specialty Hospitals

Powered by WPeMatico

Unfair and Inadequate: TN doctors oppose revised pay for Duty Medical Officers

Chennai: Several doctors across Tamil Nadu have voiced strong concerns over the state government’s recent decision to revise the minimum wages for duty medical officers working in private hospitals, calling the move ‘unfair’ and ‘inadequate’.

While the move was aimed at standardising salaries based on hospital size, many in the medical community feel that the revised pay still doesn’t do justice to their work.

Medical Dialogues, a week ago, reported that Duty Medical Officers (DMOs) working at private hospitals or nursing homes with a bed strength between 1 and 50 will now receive a revised minimum basic wage ranging from Rs 14,875 to Rs 16,057, depending on the hospital’s location. For larger hospitals with over 1,000 beds, the revised minimum wage will range between Rs 15,634 and Rs 16,876. 

This revision followed the Labour Welfare and Skill Development Department issuing a government order categorising hospitals into different zones based on geography and bed strength to determine wage levels.

Also read- TN revises minimum wages for Duty Medical Officers at private hospitals, draws criticism

But many doctors say the hike is too small and unfair, especially considering their workload. They argue that linking pay to the number of beds in a hospital is illogical since the responsibilities remain the same regardless of hospital size. The small difference in pay between small and large hospitals has also been questioned.

According to some medical experts, the new pay structure is not commensurate with the responsibilities of duty doctors and could see corporate hospitals exploiting them.

Doctors criticising the revision of the pay scale said it ridiculed their hard work and did a gross injustice to the entire profession. They feel fixing the minimum wages based on the number of beds in a hospital is absurd since there is very little margin in the pay for 50- and 1,000-bed hospitals. The fraternity is afraid that such a move could discourage people from pursuing the noble profession.

Doctors have raised concerns about being overworked, often clocking in 24 to 36 hours at a stretch without proper rest. They say the revised wages do not reflect the intensity and stress of their work.

The medical community also fears that corporate hospitals may use the revised structure to justify low pay while expecting high output from doctors. 

Speaking to The Federal, Dr GR Rabindranath, general secretary of the Doctors Association for Social Equality said, “This would only lead to private hospitals exploiting the doctors by paying them such low wages. Such practices would discourage doctors from joining the profession. The fixation of minimum wages does not have a specified criterion and is unscientific. Such a move proves that the government is favouring corporate and private hospitals, and such a low wage structure facilitates the exploitation of doctors.” 

Echoing a similar opinion, a cardiologist from Vellore working with a private healthcare institution said, “Increasing the number of seats or building new hospitals without ensuring basic facilities or care for the medical experts makes little sense. With regards to doctors’ pay, interns and postgraduates are still paid a pittance. Even professors are not paid handsomely, and they compensate by working in outside clinics. Those postgraduates who are married are constantly facing marital issues solely because of financial constraints. Somebody working 36 hours at a stretch and 100-plus work hours a week deserves something more than Rs 40,000 a month. We are not expecting to be paid in lakhs and lakhs, but at least pay the bare minimum.”

Dr V Vignesh Rajendran, president of Tamil Nadu Resident Doctors Association, said, “Even the private hospitals hiring these doctors know that the recent revision of minimum pay is very unfair. A peon or worker working in a government hospital is paid equal to that. A staff nurse is paid much more than that. What is the logic in setting the wage at Rs 16,057 per month for a 50-bed hospital and Rs 16,876 per month for a 1,000-bed hospital? How is it justified to pay just Rs 800 more for treating 950 more patients?” It sets a dangerous precedent and makes a mockery of the medical profession. It is one of the reasons why doctors from Tamil Nadu are slowly moving away and settling in other states.”

Also read- Rs 40,000 for Medical Officer Post: Doctor slams TN Govt over low pay scale

Powered by WPeMatico

Eli Lilly expands India presence with inauguration of Hyderabad site

Hyderabad: Eli Lilly and Company (India) has announced the opening of its new technology and innovation site in Hyderabad; a new strategic hub for advanced digital and technology capabilities that will improve efficiency across Lilly’s global operations.

By focusing on areas such as artificial intelligence (AI), automation, cloud computing, and software product engineering, the site will contribute to solving some of the world’s most pressing health challenges while also creating growth opportunities for local talent.

Located in Gachibowli, Lilly’s Hyderabad site spans approximately 220,000 square feet across four floors within the Phoenix Equinox building. Lilly has already onboarded 100 professionals at the Hyderabad facility and plans to expand the headcount to 1,500 over the next few years.

The facility was officially inaugurated by Diogo Rau, Executive Vice President and Chief Information and Digital Officer of Eli Lilly and Company, alongside the Hon’ble Chief Minister of Telangana, Shri A. Revanth Reddy, and Shri D. Sridhar Babu, Hon’ble Minister for IT, Electronics & Communications, Industries & Commerce, and Legislative Affairs, Government of Telangana. Sanjay Kumar, IAS, Special Chief Secretary, Industries and Commerce Department, was also present at the event.

Shri A. Revanth Reddy, Hon’ble Chief Minister of Telangana, said, We are delighted to welcome Lilly to Hyderabad’s growing life sciences ecosystem. The inauguration of this new site further reinforces the city’s position as a global hub for healthcare innovation, built on scientific excellence, skilled talent, and international collaboration. The Government of Telangana remains committed to fostering an environment where pioneering companies like Lilly can thrive and deliver meaningful impact both in India and globally.”

Shri Sridhar Babu, Hon’ble Minister for Information Technology, Electronics & Communications, Industries & Commerce and Legislative Affairs, Telangana, added, “Hyderabad is rapidly emerging as a global epicentre for digital innovation, and Lilly’s new site inauguration is a strong validation of that momentum. This investment reflects the transformative impact of technology on healthcare. Telangana remains committed to enabling future-focused partnerships that drive economic growth and advance digital health solutions for the world.”

“The inauguration of our Hyderabad site reflects our long-term commitment to India and our intent to strengthen our presence in the region,” said Diogo Rau, Executive Vice President and Chief Information and Digital Officer, Eli Lilly and Company. “This expansion brings together top talent in AI, data science, and engineering to build the digital foundation that will accelerate the discovery and delivery of innovative medicines. Hyderabad offers the perfect blend of deep technical expertise and a spirit of collaboration, making it a natural partner in our mission to make life better for people around the world. The city’s legacy of innovation runs deep—from establishing one of India’s first medical schools in 1846 to being among the earliest regions to adopt railways in recognition of the power of connectivity. Today, we are proud to build on that history by creating an integrated ecosystem that unites medicine, engineering, and digital innovation to transform how healthcare is delivered.”

“Lilly’s Hyderabad site will integrate advanced technology capabilities across key functions, supporting accelerated innovation, enhanced efficiency, and improved health outcomes for patients globally,” the company stated.

Powered by WPeMatico

Vagus nerve stimulation paired with meditation increases self-compassion and mindfulness benefits

Stimulating the vagus nerve with a device attached to the outer ear can help make compassion meditation training more effective at boosting people’s capacity for self-kindness and mindfulness, finds a new study led by University College London (UCL) researchers.

Powered by WPeMatico

New molecular technology targets tumors and simultaneously silences two ‘undruggable’ cancer genes

University of North Carolina Lineberger Comprehensive Cancer Center researchers have developed a “two-in-one” molecule that can simultaneously turn off two notoriously difficult-to-target cancer-related genes, KRAS and MYC, as well as directly deliver drugs to tumors that express these genes. This advance holds special promise for treating cancers that have been historically challenging to treat.

Powered by WPeMatico

Flawed advice on drug safety is pushing women to stop breastfeeding, says new study

The evidence supporting the health benefits of breastfeeding is overwhelming, yet many women taking medicines are being advised to stop, often unnecessarily, according to a new study from the University of Bath.

Powered by WPeMatico

Phase III study supports use of canagliflozin for type 2 diabetes in children and adolescents

A Phase III, international, randomized clinical trial assessed the safety and efficacy of canagliflozin for the treatment of type 2 diabetes mellitus (T2DM) in children and adolescents.

Powered by WPeMatico

Study finds gaps in evidence for air-cleaning technologies designed to prevent respiratory infections

A new study led by researchers from the University of Colorado Anschutz Medical Campus and the National Institute for Occupational Safety and Health (NIOSH) through the Centers for Disease Control and Prevention (CDC) finds that although many technologies claim to clean indoor air and prevent the spread of viruses like COVID-19 and the flu, most have not been tested on people and their potential risks are not yet fully understood.

Powered by WPeMatico

Over 18,900 organ transplants in 2024, says JP Nadda

New Delhi: Over 18,900 organ transplants were performed in 2024 in India – the highest in a single year, said Union Health Minister JP Nadda on Saturday. 

He was speaking at the 15th Indian Organ Donation Day organised by the National Organ and Tissue Transplant Organisation (NOTTO) under the aegis of the Directorate General of Health Services, Ministry of Health, at Dr Ambedkar International Centre, here, news agency IANS reported.

Nadda stated that the government is continuously streamlining organ donation and transplant so that more and more citizens can benefit from it.

Also Read:AIIMS, PGI Chandigarh faculty get support from Doctors’ associations for Rotatory Headship

“Since the launch of the Aadhar-based NOTTO online pledge website in 2023, more than 3.30 lakh citizens have pledged their organs to donate, marking a historic moment in public participation,” the health minister said.

Noting that surge in pledge registration reflects a growing awareness, Nadda said that “India achieved a remarkable milestone of performing over 18,900 organ transplants in 2024, the highest ever recorded in a single year”.

This is a significant leap from fewer than 5,000 transplants in 2013.

As a result, “India ranks third globally in the total number of organ transplants, behind only the US and China,” Nadda said.

Calling “organ donation one of the noblest acts of humanity”, he urged people to make the “most profound contribution for someone else.”

The Minister also highlighted the alarming rise in cases of organ failures, posing a serious threat to public health and increasing strain on the healthcare system.

“Every year, thousands of people wait for organ transplants. Despite the urgent need, there remains a significant gap between the number of patients waiting for transplants and the number of available donors.”

“This gap is not due to a lack of willingness but often due to a lack of awareness and hesitation rooted in the myths and misconceptions. That’s why today is an important day which gives us a platform to spread awareness, encourage conversation and honour the donors and their families,” Nadda said.

Underlining the government’s efforts for organ transplantation, the minister stated that “to make organ transplant more accessible, financial support of up to Rs 15 lakh is provided to poor patients for transplantation of kidneys, liver, heart and lungs under the Rashtriya Arogya Nidhi”.

“Poor patients are provided support of up to Rs 10,000 per month after transplant to cover the medical expenses. Kidney transplant package has also been included in Ayushman Bharat Pradhan Mantri- Jan Arogya Yojana (AB PM-JAY),” Nadda added.

Also Read:Jharkhand to upgrade 6 District Hospitals into Medical Colleges

Powered by WPeMatico

Tirzepatide’s Effectiveness in HFpEF linked to Baseline BMI and Fat Distribution: SUMMIT Trial

A post hoc analysis of the SUMMIT trial, published in JACC, reveals that baseline body mass index (BMI) and fat distribution significantly affect the response to tirzepatide in patients with heart failure with preserved ejection fraction (HFpEF) and obesity. Patients who lost 15% or more of their body weight experienced greater improvements in exercise capacity, blood pressure, and weight. These findings highlight the importance of baseline BMI in predicting clinical outcomes with tirzepatide therapy. The study was conducted by Barry A. and colleagues.

Obesity is a well-documented cause of HFpEF, an entity of heart failure in which cardiac pumping function is maintained but relaxation and filling are impaired. Conventional treatment has been in this subset of patients. Tirzepatide, a weekly injectable medication, engages both the glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors and is effective in weight reduction and metabolic regulation. The SUMMIT trial tested its impact in 731 obese (BMI ≥30 kg/m²) and HFpEF patients categorized under NYHA class II-IV. The patients were randomized to tirzepatide (n=364) or placebo (n=367) for 52 weeks.

This secondary analysis examined whether baseline severity of obesity (BMI) or distribution of obesity (WHR) had an effect on endpoints like cardiovascular death or HF deterioration, quality of life (KCCQ-CSS), 6-minute walk distance (6MWD), C-reactive protein (CRP), and body weight (BW). Cox regression and mixed-effects models were employed. Investigators also assessed the relationship between the magnitude of weight reduction and waist circumference decrease with tirzepatide and improvements in the major endpoints.

Key Findings:

• Younger, female patients with higher BMI had more volume overload, inflammation, and physical restriction. In BMI tertiles, tirzepatide always decreases cardiovascular death or worsening of HF risk with no heterogeneity by BMI or WHR stratum.

More increase in 6-minute walk distance:

• Estimated treatment difference (ETD): 9.9 m (low BMI) vs 26.3 m (middle BMI) vs 37.5 m (high BMI); P = 0.025

Greater weight loss:

• ETD: −10.7% vs −11.8% vs −14.4%; P = 0.006

Greater decrease in systolic BP:

• ETD: −1.00 vs −6.65 vs −6.62 mm Hg; P = 0.035

Trend towards improved quality of life (KCCQ-CSS):

• P = 0.097

In HFpEF patients with obesity, tirzepatide decreased the risk of heart failure events and cardiovascular death independent of baseline BMI or WHR. Increased BMI and WHR were linked to younger age, female gender, increased inflammatory burden, renal dysfunction, and poorer exercise capacity. These results validate the utilization of tirzepatide as an efficacious therapeutic agent for enhancing HFpEF outcomes in obese patients.

Reference:

Borlaug, B. A., Zile, M. R., Kramer, C. M., Ye, W., Ou, Y., Hurt, K., Murakami, M., Packer, M., & SUMMIT Trial Study Group. (2025). Impact of body mass index, central adiposity, and weight loss on the benefits of tirzepatide in HFpEF: The SUMMIT trial. Journal of the American College of Cardiology, 86(4), 242–255. https://doi.org/10.1016/j.jacc.2025.04.059

Powered by WPeMatico